Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.70 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24019699 | 0.84 | ALOX15 (0.72) | ALOX15ARTAS1R3TAS1R1DRD2 | |
| SCHEMBL20535295 | 0.83 | ALOX15 (0.68) | ALOX15DRD4HRH4 | |
| SCHEMBL20534721 | 0.82 | HRH4 (0.51) | ALOX15DRD4HRH4 | |
| SCHEMBL23836123 | 0.82 | ALOX15 (1.00) | ALOX15HRH4PYGL | |
| SCHEMBL24019694 | 0.82 | ALOX15 (0.70) | ALOX15ARTAS1R3TAS1R1PYGL | |
| SCHEMBL13753384 | 0.80 | DRD2 (0.68) | ALOX15TAS1R3TAS1R1PYGLDRD2 | |
| SCHEMBL30310655 | 0.80 | HRH4 (0.55) | ALOX15DRD4HRH4 | |
| SCHEMBL19966319 | 0.80 | HRH4 (0.55) | ALOX15DRD4HRH4 | |
| SCHEMBL29949076 | 0.80 | DRD2 (0.68) | ALOX15TAS1R3TAS1R1PYGLDRD2 | |
| SCHEMBL2081729 | 0.80 | HRH4 (0.55) | ALOX15DRD4HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | ALOX15 1455/4885DRD4 4772/4885HRH4 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.